GlassScriptPhysician profile
Tiffany A Serell
NPI 1104856079
$3,815.65
in general payments reported to CMS, 2019-2025
20 companies · $547 in 2025
The $547 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $366 · 2022: $458 · 2023: $1,205 · 2024: $1,239 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,716 · Education: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,715.94 |
| Education | $274.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $486.04 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $421.40 | 2023-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $392.46 | 2021-2025 | Winlevi, Ilumya |
| Lilly USA, LLC | $354.68 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $341.43 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Novartis Pharmaceuticals Corporation | $318.93 | 2023-2025 | |
| Galderma Laboratories, L.P. | $247.55 | 2021-2024 | Aklief, Oracea, Twyneo |
| Leo Pharma INC. | $168.76 | 2021-2023 | Adbry |
| Janssen Biotech, INC. | $154.74 | 2021-2025 | Tremfya, Stelara, Simponi |
| Revance Therapeutics, INC. | $137.08 | 2024 | Daxxify |
| Organon LLC | $119.73 | 2025 | Vtama |
| Pfizer INC. | $115.96 | 2021-2024 | |
| Arcutis Biotherapeutics, INC. | $109.61 | 2023-2025 | Zoryve |
| Ucb, INC. | $90.96 | 2024-2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $90.60 | 2021-2025 | Dupixent |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $86.99 | 2023-2024 | Vtama |
| Genzyme Corporation | $83.36 | 2023-2024 | |
| Almirall LLC | $46.73 | 2021 | |
| Krystal Biotech INC | $33.74 | 2024 | Vyjuvek |
| Incyte Corporation | $14.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Serell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.